Phase 3 Clinical Testing in the US of AstraZeneca COVID-19 Vaccine Candidate Begins

Having trouble viewing this email? View it as a Web page. You are receiving this message because you are subscribed to News Releases for National Institutes of Health (NIH).   Phase 3 Clinical Testing in the US of AstraZeneca COVID-19 Vaccine Candidate Begins 08/31/2020 05:00 PM EDT The trial will enroll approximately 30,000 adult volunteers at 80 sites in the United States to evaluate if the candidate vaccine can prevent symptomatic coronavirus disease 2019 (COVID-19). Update Your E-mail Address | Add Subscriptions | Unsubscribe All If you have questions or problems with the subscription service, please contact subscriberhelp.govdelivery.com. For all other inquiries about NIH programs and activities, please contact Ask NIH. Before writing, please view our Frequently Asked Questions page, our Health Information page, or Search our website. This service is provided to you by the National Institutes of Health. NIH…Turning Discovery Into Health®  This email was sent to myhcistech.healthnews360@blogger.com using GovDelivery Communications Cloud on behalf of: National Institutes of Health (NIH) · 9000 Rockville Pike · Bethesda MD 20892 · 301-496-4000 / TTY 301-402-9612